Research progress on tumor immunotherapy targeting sialic acid-Siglec complexes
10.12354/j.issn.1000-8179.2025.20241623
- VernacularTitle:靶向唾液酸-Siglec在肿瘤免疫治疗中的研究进展
- Author:
Xu QING
1
;
Duan JIARONG
;
Zheng TIANQING
Author Information
1. 天津大学(天津市 300072)
- Publication Type:Journal Article
- Keywords:
sialic acid;
Siglec;
sialidase;
targeted drug delivery;
tumor
- From:
Chinese Journal of Clinical Oncology
2025;52(2):81-85
- CountryChina
- Language:Chinese
-
Abstract:
While tumor immunotherapy has improved the prognosis of many patients,immunotherapy drug resistance develops in most tu-mors.Studies of new targets and therapies are needed to overcome this challenge.Growing evidence indicates that Siglecs function in im-mune checkpoints.Siglecs belong to a family of salivary acid-binding immunoglobulin-like lectins.The majority of Siglecs are immunosup-pressive transmembrane proteins that bind to sialic acid-containing glycans on glycoproteins and glycolipids.Sialoglycan-Siglec interactions contribute to tumor immune escape and are strongly correlated with poor prognosis in tumor patients.This review will discuss Siglec func-tion in immune checkpoints,and how the interaction between sialic acid and Siglecs regulates the tumor microenvironment to exert thera-peutic effects.
